Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Safety Study of a 1-Year 20 mg Dose Regimen of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder (N24HSWD) in Blind Individuals With No Light Perception

NCT01218789 is registered in ClinicalTrials.gov with Vanda Pharmaceuticals as lead sponsor.

NCT NCT01218789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01218789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Safety Study of a 1-Year 20 mg Dose Regimen of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder (N24HSWD) in Blind Individuals With No Light Perception
Lead sponsor
Vanda Pharmaceuticals
Phase
Phase 3
Overall status
Unknown status
Start date
October 28, 2010
Completion date
December 5, 2024
Enrollment
140 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

non 24 hour sleep wake disorder